Neurizon Therapeutics Limited has released a press release.
FDA Guidance on NUZ-001 IND Application
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- US Patent granted for NUZ-001
- Neurizon updates on NUZ-001 IND Application
- Neurizon Files IND Application to Support HEALEY ALS Trial
- Neurizon Granted OMPD for NUZ-001 in Europe
- Positive 8-month Interim Data from OLE Study
Later from Neurizon Therapeutics
- Appendix 4D - Half-year Financial Report - 31 December 2024
- Neurizon Commences Initiatives to Lift Clinical Hold
- NUZ-001 shows promising respiratory outcome
- NUZ-001 Shows Positive Results in Human 3D Brain Model
- NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics